| Literature DB >> 26091519 |
Denasha Lavanya Reddy1, Willem Daniel Francois Venter2, Sugeshnee Pather3.
Abstract
BACKGROUND: Lymphadenopathy is a common clinical presentation of disease in South Africa (SA), particularly in the era of Human Immunodeficiency Virus (HIV) and tuberculosis (TB) co-infection.Entities:
Mesh:
Year: 2015 PMID: 26091519 PMCID: PMC4474830 DOI: 10.1371/journal.pone.0130148
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Incisional, Excisional and Core Biopsy Diagnosis in relation to Demographics.
| Demographic | Malignancy, n = 219 | Necrotizing nodes, n = 125 | HIV | Not definitive, n = 170 | TOTAL, n = 560 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| KS | NHL | CHL | Car | Other | Subtotal | n(%) | |||||
| GENDER | Male | 9 | 29 | 27 | 21 | 11 | 97 | 58 | 17 | 80 | 252(45) |
| Female | 5 | 31 | 22 | 58 | 6 | 122 | 67 | 29 | 90 | 308(55) | |
| RACE | Asian | 1 | 1 | 2 | 3(0.5) | ||||||
| Black | 14 | 58 | 46 | 69 | 16 | 203 | 116 | 44 | 160 | 523(93.3) | |
| White | 2 | 9 | 11 | 3 | 1 | 9 | 24(4.2) | ||||
| Mixed Race | 2 | 1 | 1 | 4 | 4 | 1 | 1 | 10(2) | |||
| AGE | Median 40 | ||||||||||
| (12–94) | |||||||||||
| AGE BAND | 12-20yr | 4 | 5 | 2 | 11 | 11 | 1 | 18 | 41(7.3) | ||
| 21-35yr | 11 | 13 | 20 | 13 | 9 | 66 | 59 | 22 | 40 | 187(33.4) | |
| 36-50yr | 3 | 25 | 17 | 31 | 6 | 82 | 46 | 20 | 53 | 201(36) | |
| 51-65yr | 15 | 7 | 25 | 1 | 48 | 8 | 3 | 48 | 107(19) | ||
| >65yr | 3 | 8 | 1 | 12 | 1 | 11 | 24(4.3) | ||||
1HIV: Human Immunodeficiency Virus
2KS: Kaposi sarcoma
3NHL: non-Hodgkin Lymphoma
4CHL: Hodgkin Lymphoma
5Car: carcinoma.
Incisional, Excisional and Core Biopsy Diagnosis in relation to Indications and site of biopsy.
| Malignancy, n = 219 | Necrotizing nodes, n = 125 | HIV | Not definitive, n = 170 | TOTAL, n = 560 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| KS | NHL | CHL | Car | Other | Subtotal | n(%) | |||||
| INDICATION FOR BIOPSY | Suspect TB | 1 | 5 | 2 | 2 | 1 | 11 | 46 | 9 | 8 | 74(13) |
| Suspect lymphoma | 2 | 33 | 28 | 4 | 4 | 71 | 17 | 13 | 19 | 120(22) | |
| Staging Car | 60 | 60 | 54 | 114(20) | |||||||
| Uncertain Diagnosis | 9 | 16 | 14 | 12 | 9 | 60 | 45 | 20 | 77 | 202(36) | |
| Unknown | 2 | 6 | 5 | 1 | 3 | 17 | 17 | 4 | 12 | 50(9) | |
| SITE OF LYMPH NODE BIOPSY | Cervical | 8 | 26 | 37 | 18 | 9 | 98 | 73 | 16 | 31 | 218(40) |
| Inguinal | 2 | 10 | 2 | 10 | 1 | 25 | 5 | 9 | 19 | 58(10) | |
| Axilla | 2 | 11 | 7 | 35 | 6 | 61 | 18 | 12 | 38 | 129(23) | |
| Other | 2 | 13 | 3 | 16 | 1 | 35 | 29 | 9 | 82 | 155(27) | |
1HIV: Human Immunodeficiency Virus
2KS: Kaposi sarcoma
3NHL: non-Hodgkin Lymphoma
4CHL: Hodgkin Lymphoma
5Car: carcinoma
6TB: Tuberculosis.
Incisional, Excisional and Core Biopsy diagnosis in relation to HIV status.
| HIV Status | Malignancy, n = 219 | Necrotizing nodes, n = 125 | HIV | Not definitive, n = 170 | TOTAL, n = 560 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| KS | NHL | CHL | Car | Other | Subtotal | n(%) | |||||
| Subtotals | 14 | 60 | 49 | 79 | 17 | 219 | 125 | 46 | 170 | 560(100) | |
| HIV | 14 | 12 | 37 | 1 | 64 | 17 | 1 | 68 | 150(27) | ||
| HIV | 1 | 6 | 13 | 28 | 1 | 49 | 23 | 4 | 60 | 136(24) | |
| HIV | 13 | 40 | 24 | 14 | 15 | 106 | 85 | 41 | 42 | 274(49) | |
| CD4 | <100 | 7 | 4 | 3 | 14 | 35 | 2 | 6 | 57(10) | ||
| 100–200 | 3 | 13 | 5 | 5 | 2 | 28 | 19 | 5 | 6 | 58(10.4) | |
| 201–350 | 5 | 8 | 8 | 1 | 6 | 28 | 10 | 12 | 11 | 61(11) | |
| 351–500 | 2 | 2 | 5 | 1 | 10 | 1 | 7 | 4 | 22(4) | ||
| >500 | 1 | 3 | 3 | 4 | 11 | 2 | 5 | 6 | 24(4.3) | ||
| Nil/Unknown | 2 | 7 | 2 | 4 | 15 | 18 | 10 | 9 | 52(9.3) | ||
1HIV: Human Immunodeficiency Virus
2KS: Kaposi sarcoma
3NHL: non-Hodgkin Lymphoma
4CHL: Hodgkin Lymphoma
5Car: carcinoma
6CD4: Cluster of Differentiation 4 T-cells.
Statistical Agreement between LN FNA and LN Biopsy.
| Pathological Diagnosis | % observed agreements | % agreements expected by chance | Kappa | SE | 95% Confidence Interval | P-value |
|---|---|---|---|---|---|---|
| CHL | 94.09 | 76.92 | 0.744 | 0.07 | 0.606–0.882 | 0.001 |
| NHL | 92.61 | 79.50 | 0.640 | 0.07 | 0.472–0.807 | 0.001 |
| Car | 96.55 | 87.55 | 0.723 | 0.069 | 0.528–0.918 | 0.001 |
| Granulom inflam NOS | 97.04 | 95.20 | 0.385 | 0.07 | -0.005–0.775 | 0.001 |
| MI | 89.16 | 60.49 | 0.726 | 0.07 | 0.618–0.833 | 0.001 |
| Non-specific reactive LNH | 80.30 | 67.28 | 0.398 | 0.067 | 0.249–0.547 | 0.001 |
1CHL: Hodgkin Lymphoma
2NHL: non Hodgkin Lymphoma
3Car: carcinoma
4Granulom inflam NOS: Granulomatous Inflammation not otherwise specified
5MI: Mycobacterial Infection
6Non-specific reactive LNH: non-specific reactive lymph node hyperplasia.